Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

33.80
+0.15000.45%
Volume:124.96K
Turnover:4.25M
Market Cap:6.98B
PE:-12.00
High:34.24
Open:34.10
Low:33.71
Close:33.65
52wk High:45.42
52wk Low:15.95
Shares:206.40M
Float Shares:89.57M
Volume Ratio:0.27
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8178
EPS(LYR):-2.7716
ROE:-80.10%
ROA:-46.73%
PB:9.49
PE(LYR):-12.19

Loading ...

UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating

MT Newswires Live
·
Aug 24

UBS Remains a Hold on Immunovant (IMVT)

TIPRANKS
·
Aug 24

Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype

Simply Wall St.
·
Aug 15

Immunovant, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Immunovant Fiscal Q1 2027 Results: IMVT-1402 Spending Widens Net Loss

TradingKey
·
Aug 06

Immunovant reports Q2 EPS (75c), consensus (61c)

TIPRANKS
·
Aug 06

Immunovant FY27 Q1 Net Loss Widens 27% to $153.2 Million; R&D Expenses Rise 40.9% to $142.6 Million

Reuters
·
Aug 06

Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss

MT Newswires Live
·
Aug 06

Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate

Benzinga Earnings
·
Aug 06

Immunovant Q1 Net Income USD -153.224 Million Vs. IBES Estimate USD -130.2 Million

Reuters
·
Aug 06

Immunovant, - Cash and Cash Equivalents Total $797.80 Mln as of June 30, 2026

THOMSON REUTERS
·
Aug 06

J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)

TIPRANKS
·
Aug 04

Earning Preview: Immunovant, Inc. Q2 revenue is expected to be flat, and institutional views are predominantly bullish

Earnings Agent
·
Jul 31

Roivant President, Immunovant CEO Eric Venker Sells USD 6.99 Million in Common Shares

Reuters
·
Jul 30

Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $59,700

Reuters
·
Jul 25

Immunovant Updates Financial Calendar with First-quarter Results Release and Business Update Call

Reuters
·
Jul 24

Immunovant Announces Annual Shareholder Meeting

Reuters
·
Jul 23

Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million

Reuters
·
Jul 07

Chief Technology Officer Of Immunovant Sold 53% Of Their Shares

Simply Wall St.
·
Jul 02

Immunovant is Maintained at Buy by Citigroup

Dow Jones
·
Jul 01